TITLE

NF

PUB. DATE
January 2005
SOURCE
Taber's Cyclopedic Medical Dictionary;2005, p1467
SOURCE TYPE
Book
DOC. TYPE
Reference Entry
ABSTRACT
A definition of the term "NF" is presented, which means National Formulary.
ACCESSION #
21237645

 

Related Articles

  • 'Cross-Omics' and Systems Toxicology. Zingler, Kurt // Bio-IT World;Nov2007, Vol. 6 Issue 9, p25 

    The author comments on systems toxicology approaches in drug development. According to the author, in the integration of toxicogenomic data with conventional toxicological endpoints, researchers often lack efficient workflow, the ability to decide based on integrated information, and access to...

  • CALENDAR.  // Pharmaceutical Technology Europe;Dec2005, Vol. 17 Issue 12, p14 

    The article presents calendar of events in Great Britain related to pharmaceutical industry. Innovating Clinical Drug Development will be on January 25-26, 2005. Process Analytical Technologies will be held on January 26-27, Pharmaceutical Quality Assurance and Control on February 6-10, 2005....

  • CALENDAR.  // Drug Discovery & Development;Apr2004, Vol. 7 Issue 4, p76 

    Presents schedules of congresses about drug discovery and development. Title of the congresses; Association; Web site; Location.

  • Critical Path Initiative unveils list of 76 project priorities.  // Inside Tucson Business;3/20/2006, Vol. 15 Issue 41, p3 

    The article reports that the Critical Path Institute in Tucson, Arizona has unveiled its Opportunities List of project priorities which is designed to modernize the drug development process by 2010 and to enhance medical discoveries at a lower cost.

  • Clinical research companies form association.  // Pharmaceutical Technology North America;May2002, Vol. 26 Issue 5, p96 

    Reports the formation of the Association of Clinical Research Organizations by clinical research companies in the U.S. Representation of the drug development industry; Participation of health policy debates; Concerns on patient safety.

  • Maintaining the Cold Chain. Forcinio, Hallie // Pharmaceutical Technology;Mar2006, Vol. 30 Issue 3, p44 

    The article reports on the Parenteral Drug Association's issuance of Technical Report No. 39 "Cold Chain Guidance for Medicinal Products: Maintaining the Quality of Temperature-Sensitive Medicinal Products through the Transportation Environment". The guidance discusses how to develop protective...

  • Public-Private Partnership for Tuberculosis Drugs Development Appoints CEO.  // Ascribe Newswire: Health;8/1/2001, p16 

    Maria C. Freire has been chosen as the new chief executive officer of the Global Alliance for TB Drug Development. Freire's extensive technology management expertise, her understanding and passion for scientific research, her proven ability to build and manage organizations, and her commitment...

  • TB: Ten Years After.  // Time;3/2/1962, Vol. 79 Issue 9, p53 

    The article reports on the significance of a new drug isoniazid or isonicotinic acid hydrazide (INH) in helping speed up the recovery of tuberculosis (TB) patients in Manhattan, New York. It states that the National Tuberculosis Association surveyed what might still be developed to treating TB...

  • AAN/AES Guidelines on Use of New AEDS. Ben-Menachem, Elinor // Epilepsy Currents;Jan/Feb2005, Vol. 5 Issue 1, p30 

    Presents a study which assessed the evidence demonstrating efficacy, tolerability and safety of several antiepileptic drugs. Drugs approved by the U.S. Food and Drug Administration for the treatment of children and adults with newly diagnosed partial and generalized epilepsies; Guidelines used...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics